Pharmacovigilance medical reviewer must resolve whether the primary endpoint

Situation

In a safety team sitting on a new disproportionate signal, biosimilar analytical similarity report is the evidence after an inspector asking for batch records you cannot produce this week. Pharmacovigilance medical reviewer has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences FDA Response and Labeling close using biosimilar analytical similarity report.

Decision

Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• Authorize Proceed under protocol now; biosimilar analytical similarity report already has the discriminator after an inspector asking for batch records you cannot produce this week.
• Keep Pause the pathway in force until biosimilar analytical similarity report is completed after an inspector asking for batch records you cannot produce this week for pharmacovigilance medical reviewer.
• Treat biosimilar analytical similarity report as Escalate safety review because both readings appear after an inspector asking for batch records you cannot produce this week.
• Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the page the primary endpoint will turns on in biosimilar analytical similarity report.

Analysis required

• Check whether biosimilar analytical similarity report supports the labeled claim pharmacovigilance medical reviewer would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week.
• For this Pharma & Life Sciences FDA Response and Labeling file, read biosimilar analytical similarity report against an inspector asking for batch records you cannot produce this week and write the one fact that would move the primary endpoint will for pharmacovigilance medical reviewer.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week). If biosimilar analytical similarity report cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. If biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences FDA Response and Labeling close, pharmacovigilance medical reviewer must state the unresolved clinical or safety evidence requirement explicitly.